Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Lung Cancer

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2005.06.010PMID 16139391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group

  2006cited by this paper
• Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

  2005cited by this paper
• Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.

  2005cited by this paper
• Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

  2005cited by this paper
• Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.

  2005cited by this paper
• Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.

  2005cited by this paper
• Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

  2005influential reference
• Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.

  2005cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC).

  2004cited by this paper
• A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

  2004cited by this paper
• Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

  2004influential reference
• Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)

  2004cited by this paper
• Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

  2004cited by this paper
• Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

  2004cited by this paper
• Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.

  2004cited by this paper
• A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

  2004cited by this paper
• Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial.

  2004cited by this paper
• The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC).

  2004cited by this paper
• Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.

  2004cited by this paper
• Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

  2004cited by this paper
• Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

  2003cited by this paper
• Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

  2003cited by this paper
• Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.

  2003cited by this paper
• Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

  2003cited by this paper
• O-89 S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial

  2003cited by this paper
• 774 Quality of life assessment and final results of a randomized Phase II study with single-agent gemcitabine and docetaxel given sequentially every 3 weeks show effective treatment in advanced NSCLC

  2003cited by this paper
• Chemotherapeutic management of stage IV non-small cell lung cancer.

  2003influential reference
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

  2002cited by this paper
• Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.

  2002cited by this paper
• Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

  2002cited by this paper
• Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

  2002cited by this paper
• Allocation concealment in randomised trials: defending against deciphering.

  2002cited by this paper
• Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review

  2002cited by this paper
• Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma

  2002cited by this paper
• Key Topics in Evidence-Based Medicine

  2001cited by this paper
• Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.

  2001cited by this paper
• Global cancer statistics in the year 2000.

  2001cited by this paper
• Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.

  2001cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

  2000cited by this paper
• Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.

  2000cited by this paper
• Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).

  2000cited by this paper
• Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

  2000cited by this paper
• Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

  2000cited by this paper
• Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

  2000cited by this paper
• Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

  2000influential reference
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

  2000cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (PD) then vinorelbine (V) versus V-C until PD then D

  2000cited by this paper
• A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

  2000cited by this paper
• Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.

  1999cited by this paper
• Taxol and cisplatin (TP) versus etoposide cisplatin (EP) in advanced non-small cell lung cancer (NSCLC)

  1999cited by this paper
• Assessment of the new postsurgical pathological staging classification in NSCLC

  1999cited by this paper
• Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

  1998cited by this paper
• Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

  1998cited by this paper
• The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

  1995cited by this paper
• The taxoids: paclitaxel and docetaxel.

  1994cited by this paper
• Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

  1993cited by this paper

• (-)-Epi-Osmundalactone-Rich Fraction from Angiopteris evecta Suppresses Proliferation and Induces Intrinsic Apoptosis in Non-Small Cell Lung Cancer Cells via MAPK Pathway Modulation

  2026cites this paper
• The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury

  2025cites this paper
• Concurrent Analysis of Antioxidant and Pro-Oxidant Activities in Compounds from Plant Cell Cultures

  2025cites this paper
• Serum Amyloid A1 Mediates Paclitaxel Resistance via MD2‐Dependent Pathways in Triple‐Negative Breast Cancer

  2025cites this paper
• Investigation of the sensitivity of human A549 cells to paclitaxel and sesquiterpene lactone alantolactone via apoptosis induction

  2025cites this paper
• Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study

  2024cites this paper
• Acyl Urea Compounds Therapeutics and its Inhibition for Cancers in Women: A Review.

  2024cites this paper
• Clinical efficacy and safety of Chinese herbal injections in combination with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis of 140 randomized controlled trials

  2024cites this paper
• Surface and mechanical properties of polyurethane central venous catheters after repeated contact with chemotherapy excipient solutions.

  2023cites this paper
• Ruthenium complexes for breast cancer therapy

  2023cites this paper
• Recent Progress in Drug Delivery Systems for Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer.

  2023cites this paper
• Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits

  2022cites this paper
• Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells

  2022cites this paper
• State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent

  2022influential citation
• A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer

  2022cites this paper
• PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.

  2021cites this paper
• Study of the Effect Epidermal Growth Factor Nanoparticles in the Treatment of Diabetic Rat Ulcer Skin and Regeneration.

  2021cites this paper
• Paclitaxel Impedes EGFR-mutated PC9 Cell Growth via Reactive Oxygen Species-mediated DNA Damage and EGFR/PI3K/AKT/mTOR Signaling Pathway Suppression

  2021cites this paper
• Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer

  2021cites this paper
• Future Therapeutic Directions for Smac-Mimetics

  2020cites this paper
• Synthesis of spheroid shaped silver nanoparticles using Indian traditional medicinal plant Flacourtia indica and their in vitro anti-proliferative activity

  2019cites this paper
• Emerging roles of microRNAs as a regulator in the progression of lung cancer and their implications in its diagnosis and therapy

  2019cites this paper
• Paclitaxel interaction with cucurbit [7]uril and acyclic Cucurbit[4]uril nanocontainers: A computational approach.

  2019cites this paper
• Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs

  2018cites this paper
• Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer

  2018influential citation
• Substituents at the C3′ and C3′N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel

  2018cites this paper
• Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

  2018influential citation
• Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid–polymer hybrid nanoparticles

  2018cites this paper
• Aurora B expression modulates paclitaxel response in non-small cell lung cancer

  2017cites this paper
• Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

  2017cites this paper
• Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1)

  2017influential citation
• Non-invasive approaches for lung cancer diagnosis

  2017cites this paper
• Efficacy and safety of nitroglycerin combined with chemotherapy in the elderly patients with advanced non-small cell lung cancer complicated with coronary heart disease

  2016cites this paper
• Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles.

  2016cites this paper
• LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

  2016cites this paper
• Molecular characterisation of renal cell carcinoma and related disorders

  2016cites this paper
• Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer

  2015cites this paper
• An investigation of nitrile transforming enzymes in the chemo-enzymatic synthesis of the taxol sidechain.

  2015cites this paper
• Controlled delivery of Gemcitabine Hydrochloride using mannosylated poly(propyleneimine) dendrimers

  2015cites this paper
• Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.

  2015cites this paper
• Constitutive Androstane Receptor Ligands Modulate the Anti-Tumor Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells

  2014cites this paper
• Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers

  2014cites this paper
• Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

  2014cites this paper
• EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.

  2014cites this paper
• A LOCALIZED CONTROLLED DELIVERY SYSTEM UTILIZING A BLOCK COPOLYMER TO IMPROVE THE CURRENT PARADIGM OF CHEMOTHERAPY

  2013cites this paper
• A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

  2013cites this paper
• Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.

  2013cites this paper
• Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel.

  2013cites this paper
• Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells.

  2013cites this paper
• Identification of transcription factors controlling the expression of paclitaxel biosynthesis genes in cambial meristematic cells of Taxus cuspidata

  2013cites this paper
• First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

  2013cites this paper
• Taxol, Camptothecin and Beyond for Cancer Therapy

  2012cites this paper
• Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).

  2011cites this paper
• Randomized phase II study comparing docetaxel plus cisplatin , docetaxel plus carboplatin , and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma : a Japanese Gynecologic Oncology Group study ( JGOG 2041 )

  2011cites this paper
• miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo

  2011cites this paper
• Clinical observation of docetaxel plus cisplatin versus gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer

  2011cites this paper
• DNA-targeted drugs

  2011cites this paper
• RNA interference for improving the outcome of islet transplantation and polymeric micelle-based nanomedicine for cancer therapy

  2011cites this paper
• Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells

  2011influential citation
• Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel‐induced neuropathy

  2011cites this paper
• Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer.

  2010cites this paper
• Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100.

  2010cites this paper
• Near-infrared light triggers release of Paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity.

  2010cites this paper
• Best supportive care in lung cancer trials is inadequately described: a systematic review.

  2010cites this paper
• Clinical study of comparing LP and TP regimens in the treatment of advanced non-small cell lung cancer

  2010cites this paper
• New medical applications of plant secondary metabolites

  2010cites this paper
• Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats.

  2009cites this paper
• Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer.

  2009cites this paper
• HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.

  2009cites this paper
• Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer

  2009cites this paper
• Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma

  2009cites this paper
• First- and second-line therapy for advanced nonsmall cell lung cancer

  2009cites this paper
• The role of Bcl-xL and nuclear factor-κB in the effect of taxol on the viability of dendritic cells

  2009cites this paper
• Phase III trials of neo‐adjuvant chemotherapy in Stage IIIA non‐small cell lung cancer – does size matter?

  2009cites this paper
• Chemotherapy In Advanced Non-Small Cell Lung Cancer : A Review

  2008cites this paper
• Treatment for lung metastasis from head and neck squamous cell carcinoma: a preliminary study of docetaxel

  2008cites this paper
• Chemotherapy In Advanced Non-Small Cell Lung Cancer: A Review

  2008cites this paper
• The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

  2008cites this paper
• The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.

  2008cites this paper
• Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer

  2008cites this paper
• Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

  2008cites this paper
• Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

  2007cites this paper
• Bevacizumab for non-small-cell lung cancer.

  2007cites this paper
• Determination of carboplatin dose by area under the curve in combination chemotherapy for senile non-small cell lung cancer

  2007cites this paper
• Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

  2007cites this paper
• [Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results].

  2007cites this paper
• Bevacizumab for non-small-cell lung cancer.

  2007cites this paper
• AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

  2007cites this paper
• The egg trade--making sense of the market for human oocytes.

  2007cites this paper
• Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.

  2007cites this paper
• Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group

  2006cites this paper
• European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease

  2006cites this paper
• Lyoprotected nanosphere formulations for paclitaxel controlled delivery.

  2006cites this paper
• Taxane pharmacogenetics.

  2006cites this paper
• Development of a piezoelectric immunosensor for the measurement of paclitaxel.

  2006cites this paper
• Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer

  2006cites this paper
• NitroglycerinTreatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma

  2006cites this paper
• Taxanes in paediatric oncology: and now?

  2006cites this paper
• Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma

  2006cites this paper
• The War on Cancer: A Report from the Front Lines

  2006cites this paper